ARTBIO: Valuation, Funding & Investors
ARTBIO is a biotechnology company specializing in the development of alpha radioligand therapies. The company is focused on advancing its lead asset, AB001, through clinical development and progressing additional programs toward investigational new drug (IND) readiness. ARTBIO also emphasizes expanding its manufacturing and supply chain infrastructure, utilizing its proprietary generator technology to enhance its operations.
Leadership & Board
- Current Number of Employees
- 77
- Current LinkedIn Followers
- 13,333
Latest Estimated Valuation
- Total Amount Raised
- $132M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $132M
- Latest Funding Round
- Series B
Employee Trend
ARTBIO had 77 employees as of November 16, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
ARTBIO had 13,333 followers as of November 16, 2026. The number of followers increased by 20 (0.15%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Jul 29, 2025 | Series B | $132.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Omega Funds | Series B |
| B Capital Group | Series B |
| Alexandria Venture Investments | Series B |
| F-Prime | Series B |
| Third Rock Ventures | Series B |
| Qatar Investment Authority | Series B |
| Sofinnova Investments | Series B |
Similar Companies
A snapshot of private companies similar to ARTBIO, helping you discover and navigate related company profiles.










